| name | es-gh-contraindication-spinal-irradiation |
| description | This skill determines whether growth hormone (GH) treatment is contraindicated for short stature in childhood cancer survivors without confirmed growth hormone deficiency (GHD) who have a history of spinal irradiation (e.g., total-body irradiation, craniospinal irradiation). It is triggered by clinician questions such as "Can I use GH for short stature after spinal radiation?" or "Is GH appropriate for growth impairment post-CSI/TBI?" |
Assess GH contraindication post-spinal irradiation
STEP 1 — Gather Information
Collect history of spinal irradiation (total-body irradiation, craniospinal irradiation, or radiation involving the spine), document short stature/poor linear growth (height <-2 SDS or declining growth velocity), confirm absence of GHD via appropriate provocative testing (e.g., insulin tolerance test, glucagon, arginine) per guideline, and verify patient is disease-free for at least 1 year if considering GH.
STEP 2 — Rule In / Rule Out
Determine if GHD is confirmed. If GHD is present, GH may be considered (not contraindicated per this rule); if GHD is not confirmed, proceed to contraindication assessment for spinal irradiation.
STEP 3 — Classify or Stratify
If no GHD and history of spinal irradiation, classify as GH contraindicated for short stature; if GHD present, classify as potential candidate for GH therapy (subject to other guidelines).
STEP 4 — Decide
If contraindicated, refrain from initiating GH for short stature; focus on monitoring growth, evaluating other causes (e.g., spinal foreshortening, nutritional, endocrine), and consider supportive measures. If GHD confirmed, discuss GH initiation with oncology team, ensuring disease-free status and baseline assessments.
Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on low IGF-I or spontaneous GH secretion to rule out GHD; avoid GH in patients with active malignancy; be aware that GH may worsen disproportionate growth (spinal vs leg) and scoliosis after spinal irradiation; do not use GH to treat short stature without confirming GHD; avoid GH in patients receiving tyrosine kinase inhibitors (per 1.4).
Concrete Clinical Example
A 10-year-old survivor of acute lymphoblastic leukemia who received TBI 12 Gy at age 4 presents with height -2.2 SDS and normal GH stimulation test (peak GH 8 ng/mL). The clinician considers GH for short stature but, per this skill, refrains because GHD is not confirmed and there is a history of spinal irradiation.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-01175
